Status:
COMPLETED
Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The drug regimes in treating ankylosing spondylitis(AS) have limitations. The tumor necrosis factor inhibitors(TNFi) was effective but expensive. Disease modifying anti-rheumatic drugs (DMARDs) were c...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Ankylosing Spondylitis(AS) based on modified New York diagnostic criteria for AS (1984) 2.At the mild-to-moderate stage of AS disease 3.At the active phase of AS disease
Exclusion
- Active tuberculosis, hepatitis, tumors, infection diseases or combine with other rheumaimmune systemic diseases or osteoarthritis diseases 2.Pregnant or breastfeeding women
Key Trial Info
Start Date :
December 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2019
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT03411798
Start Date
December 15 2017
End Date
July 1 2019
Last Update
August 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital
Guangzhou, Guangdong, China, 510515